Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDGL Stock Price Chart Interactive Chart >
MDGL Price/Volume Stats
|Current price||$65.24||52-week high||$105.93|
|Prev. close||$67.36||52-week low||$52.33|
|Day high||$70.46||Avg. volume||230,269|
|50-day MA||$69.16||Dividend yield||N/A|
|200-day MA||$74.09||Market Cap||1.12B|
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
Most Popular Stories View All
MDGL Latest News Stream
|Loading, please wait...|
MDGL Latest Social Stream
View Full MDGL Social Stream
Latest MDGL News From Around the Web
Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Haemonetics (HAE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL – Research Report) and Haemonetics (HAE – Research Report). Madrigal Pharmaceuticals (MDGL) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $182.00. The company's shares closed last Monday at $64.62. According to TipRanks.
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH cirrhosisScreening data from the Phase 3 MAESTRO-NASH biopsy study provide new insights on noninvasive strategies for patient identification Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Nov. 03, 2022 (GLOBE NEWSWIR
E ratio of -4.90.
As biotech companies take new shots at fatty liver disease, investor skepticism and potential payoffs are high.
NASH is a common disease, but there are no approved treatments for it. These two drug companies have promising candidates in clinical trials.
MDGL Price Returns